checkAd

     125  0 Kommentare Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss - Seite 3

    Contacts

    Media:
    Katie Engleman, 1AB
    katie@1abmedia.com

    Lesen Sie auch

    Investors:
    Courtney Turiano, Stern Investor Relations
    Courtney.Turiano@sternir.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Akouos Receives Orphan Drug and Rare Pediatric Disease Designations for AK-OTOF for the Treatment of Otoferlin Gene-Mediated Hearing Loss - Seite 3 BOSTON, April 13, 2021 (GLOBE NEWSWIRE) - Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the …